Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous

Case Reports in Ophthalmology

Volumn 4, Issue 1, 2013, Pages 7-10

  Ozsutcu, Mustafa ^a   Gulkilik, Gokhan ^b,c   Ayintap, Emre ^a   Altinisik, Muhammed ^a   Demirci, Goktug ^b   Aras, Cengiz ^a  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^c Naima Sok   (Turkey)

Author keywords

Bevacizumab; Diabetic macular edema; Posterior vitreous; Vitreomacular traction

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

ADULT; ANTERIOR EYE SEGMENT; ARTICLE; CAPILLARY LEAK SYNDROME; CASE REPORT; CENTRAL FOVEA THICKNESS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE EXACERBATION; FEMALE; HUMAN; INFORMED CONSENT; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOUS BODY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA MACULOPATHY; RETINAL THICKNESS; SLIT LAMP; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITREOMACULAR TRACTION; VITREOUS BODY; VITREOUS DISEASE; BIOMICROSCOPY; ENDOPHTHALMITIS; EYE FUNDUS; MACULAR THICKNESS; RETINA DETACHMENT; UVEITIS; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84877949023     PISSN: None     EISSN: 16632699     Source Type: Journal    
DOI: 10.1159/000342873     Document Type: Article

References (8)

1. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
2. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-1497.
3. Gunther JB, Altaweel MM: Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
4. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005. (Pubitemid 44973218)
5. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349. (Pubitemid 44702055)
6. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; Pan American Collaborative Retina Group (PACORES): Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
7. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG: Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-216. (Pubitemid 351224097)
8. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.